Planning and determination of the modulation of the carotid body

The present Dende disclosure relates to methods, devices and systems for planning and optional determining the effective and safe complete or partial ablation of one or both carotid bodies, carotid body ( "CB") chemoreceptors or nerves of the carotid body for the treatment of patients with sympathetically mediated cardiac, metabolic and pulmonary disease (e.g., as high blood pressure, CHF, diabetes, sleep-disordered breathing) resulting from peripheral chemoreceptor hypersensitivity, hyperactivity of the carotid body, high afferent Nervensignalgebung carotid body or increased sympathetic activation.